Skip to Content

Odefsey Dosage

Generic name: emtricitabine 200mg, rilpivirine hydrochloride 25mg, tenofovir alafenamide fumarate 25mg
Dosage form: tablet

Medically reviewed on August 28, 2017.

Testing Prior to Initiation of ODEFSEY

Prior to initiation of ODEFSEY, patients should be tested for hepatitis B virus infection [see Warnings and Precautions (5.1)].

It is recommended that serum creatinine, serum phosphorus, estimated creatinine clearance, urine glucose, and urine protein should be assessed before initiating ODEFSEY and during therapy in all patients as clinically appropriate [see Warnings and Precautions (5.8)].

Recommended Dosage

ODEFSEY is a 3-drug fixed dose combination product containing 200 mg of emtricitabine (FTC), 25 mg of rilpivirine (RPV), and 25 mg of tenofovir alafenamide (TAF). The recommended dosage of ODEFSEY is one tablet taken orally once daily with a meal in the following patient population: adults and in pediatric patients 12 years of age and older with body weight greater than or equal to 35 kg and a creatinine clearance greater than or equal to 30 mL per minute [see Clinical Pharmacology (12.3)].

Testing After Initiation of ODEFSEY

In virologically-suppressed patients, additional monitoring of HIV-1 RNA and regimen tolerability is recommended after replacing therapy to assess for potential virologic failure or rebound [see Clinical Studies (14)].

Not Recommended in Patients with Severe Renal Impairment

ODEFSEY is not recommended in patients with estimated creatinine clearance below 30 mL per minute [see Warnings and Precautions (5.8) and Use in Specific Populations (8.6)].

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

More about Odefsey (emtricitabine / rilpivirine / tenofovir alafenamide)

Consumer resources

Professional resources

Related treatment guides